Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia

European Journal of Neurology

Volumn 18, Issue 4, 2011, Pages 564-570

  Broccoletti, T ^a   Del Giudice, E ^a   Cirillo, E ^a   Vigliano, I ^a   Giardino, G ^a   Ginocchio, V M ^a   Bruscoli, S ^b   Riccardi, C ^b   Pignata, C ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Ataxia telangiectasia; Betamethasone; Glucocorticoid induced leucine zipper

Indexed keywords

BETAMETHASONE; GLUCOCORTICOID INDUCED LEUCINE ZIPPER; GLUCOCORTICOID RECEPTOR; LEUCINE ZIPPER PROTEIN; RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; SCALE FOR THE ASSESSMENT AND RATING OF ATAXIA; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ATAXIA TELANGIECTASIA; BETAMETHASONE; BIOLOGICAL MARKERS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952721979     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03203.x     Document Type: Article

References (34)

1. Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair 2008; 7: 1028-1038.
2. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair 2004; 3: 1187-1196.
3. Gatti RA, Becker-Catania S, Chun HH, et al. The pathogenesis of ataxia-telangiectasia. Learning from a Rosetta Stone. Clin Rev Allergy Immunol 2001; 20: 87-108.
4. Frappart PO, McKinnon PJ. Ataxia-Telangiectasia and related diseases. Neuromolecular Med 2006; 8: 495-511.
5. Katyal S, McKinnon PJ. DNA repair deficiency and neurodegeneration. Cell Cycle 2007; 6: 2360-2365.
6. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22: 5612-5621.
7. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008; 9: 759-769.
8. Taylor AMR, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005; 58: 1009-1015.
9. Ball LG, Xiao W. Molecular basis of ataxia telangiectasia and related diseases. Acta Pharmacol Sin 2005; 26: 897-907.
10. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair 2002; 1: 3-25.
11. Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol 2002; 71: 9-15.
12. Wikstrom AC. Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness. J Endocrinol 2003; 178: 331-337.
13. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor {kappa}B. Blood 2001; 98: 743-753.
14. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child 2006; 91: 610-611.
15. Lavin MF, Gueven N, Bottle S, Gatti RA. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Br Med Bull 2007; 81-82: 129-147.
16. Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol 2008; 15: 223-228.
17. Russo I, Cosentino C, Del Giudice E, et al. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol 2009; 16: 755-759.
18. Schmitz-Hubsch T, Tezenas du Montcel S, Baliko L, et al. Scale for the assessment and rating of ataxia. Neurology 2006; 66: 1717-1720.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
20. Stewart GS, Last JI, Stankovic T, et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients with 5762ins137 and 7271T-->G mutations, showing a less severe phenotype. J Biol Chem 2001; 276: 30133-30141.
21. Barzilai A, Biton S, Shilol Y. The role of the DNA damage response in neuronal development, organization and maintenance. DNA Repair 2008; 7: 1010-1027.
22. McKinnon PJ. Ataxia telangiectasia: new neurons and ATM. Trends Mol Med 2001; 7: 233-234.
23. Barlow C, Dennery PA, Shigenaga MK, et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. Proc Natl Acad Sci USA 1999; 96: 9915-9919.
24. Chen P, Peng C, Luff J, et al. Oxidative Stress Is Responsible for Deficient Survival and Dendritogenesis in Purkinje Neurons from ataxia-teleangiectasia mutated mutant mice. J Neurosci 2003; 36: 11453-11460.
25. Bruscoli S, Di Virgilio R, Donato V, et al. Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis. Eur J Pharmacol 2006; 529: 63-70.
26. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-78.
27. D'Adamio F, Zollo O, Moraca R, et al. A New Dexamethasone-Induced Gene of the Leucine Zipper Family Protects T Lymphocytes from TCR/CD3-Activated Cell Death. Immunity 1997; 7: 803-812.
28. Riccardi C, Bruscoli S, Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 2002; 45: 361-368.
29. Cannarile L, Zollo O, D'Adamio F, et al. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene. Cell Death Differ 2001; 8: 201-203.
30. Yachi K, Inoue K, Tanaka H, Yoshikawa H, Tohyama M. Localization of glucocorticoid-induced leucine zipper (GILZ) expressing neurons in the central nervous system and its relationship to the stress response. Brain Res 2007; 1159: 141-147.
31. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
32. Riccardi C, Cifone MG, Migliorati G. Glucocorticoid hormone-induced modulation of gene expression and regulation of T-cell death: role of GITR and GILZ, two dexamethasone-induced genes. Cell Death Differ 1999; 6: 1182-1189.
33. Riccardi C, Zollo O, Nocentini G, et al. Glucocorticoid hormones in the regulation of cell death. Therapie 2000; 55: 165-169.
34. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004; 144: 505-511.